Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 306

1.

Which one? What kind? How many? Types, causes, and prevalence of disability among U.S. adults.

Theis KA, Steinweg A, Helmick CG, Courtney-Long E, Bolen JA, Lee R.

Disabil Health J. 2019 Jul;12(3):411-421. doi: 10.1016/j.dhjo.2019.03.001. Epub 2019 Mar 28.

PMID:
31000498
2.

Differences in Length of Stay and Costs Between Comparable Hospitalizations of Patients With Spina Bifida With or Without Pressure Injuries.

Wang Y, Ouyang L, Dicianno BE, Beierwaltes P, Valdez R, Thibadeau J, Bolen J.

Arch Phys Med Rehabil. 2019 Aug;100(8):1475-1481. doi: 10.1016/j.apmr.2018.12.033. Epub 2019 Jan 24.

3.

Gender difference in clinical conditions among hospitalized adults with myotonic dystrophy.

Ouyang L, Wang Y, Valdez R, Johnson N, Gutmann L, Street N, Bolen J.

Muscle Nerve. 2019 Mar;59(3):348-353. doi: 10.1002/mus.26402. Epub 2019 Jan 13.

PMID:
30575975
4.

Evaluating Implementation of the Updated Care Considerations for Duchenne Muscular Dystrophy.

Ong KS, Kinnett K, Soelaeman R, Webb L, Bain JS, Martin AS, Westfield C, Bolen J, Street N.

Pediatrics. 2018 Oct;142(Suppl 2):S118-S128. doi: 10.1542/peds.2018-0333N.

5.

Muscular Dystrophy Surveillance, Tracking, and Research Network pilot: Population-based surveillance of major muscular dystrophies at four U.S. sites, 2007-2011.

Do TN, Street N, Donnelly J, Adams MM, Cunniff C, Fox DJ, Weinert RO, Oleszek J, Romitti PA, Westfield CP, Bolen J; Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).

Birth Defects Res. 2018 Nov 15;110(19):1404-1411. doi: 10.1002/bdr2.1371. Epub 2018 Aug 2.

PMID:
30070776
6.

Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan DW, Bolen J, Weber DR, Ward LM; DMD Care Considerations Working Group.

Lancet Neurol. 2018 Apr;17(4):347-361. doi: 10.1016/S1474-4422(18)30025-5. Epub 2018 Feb 3. Review.

7.

Safety Evaluation of Lipid Nanoparticle-Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey.

Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, Bolen J, Hoge S, Bulychev A, Jacquinet E, Bartlett V, Smith PF.

Vet Pathol. 2018 Mar;55(2):341-354. doi: 10.1177/0300985817738095. Epub 2017 Nov 30.

PMID:
29191134
8.

The Future of Fragile X Syndrome: CDC Stakeholder Meeting Summary.

Riley C, Mailick M, Berry-Kravis E, Bolen J.

Pediatrics. 2017 Jun;139(Suppl 3):S147-S152. doi: 10.1542/peds.2016-1159B. No abstract available.

9.

Clinical Follow-Up for Duchenne Muscular Dystrophy Newborn Screening: A Proposal.

Kwon JM, Abdel-Hamid HZ, Al-Zaidy SA, Mendell JR, Kennedy A, Kinnett K, Cwik VA, Street N, Bolen J, Day JW, Connolly AM.

Muscle Nerve. 2016 Aug;54(2):186-91. doi: 10.1002/mus.25185. Epub 2016 Jun 13.

10.

Public Health and Rare Diseases: Oxymoron No More.

Valdez R, Ouyang L, Bolen J.

Prev Chronic Dis. 2016 Jan 14;13:E05. doi: 10.5888/pcd13.150491. No abstract available. Erratum in: Prev Chronic Dis. 2016;13:E20.

11.

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors.

Sells TB, Chau R, Ecsedy JA, Gershman RE, Hoar K, Huck J, Janowick DA, Kadambi VJ, LeRoy PJ, Stirling M, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Balani SK, Bolen JB, Manfredi MG, Claiborne CF.

ACS Med Chem Lett. 2015 Apr 22;6(6):630-4. doi: 10.1021/ml500409n. eCollection 2015 Jun 11.

12.

Predicting the composition of red wine blends using an array of multicomponent Peptide-based sensors.

Ghanem E, Hopfer H, Navarro A, Ritzer MS, Mahmood L, Fredell M, Cubley A, Bolen J, Fattah R, Teasdale K, Lieu L, Chua T, Marini F, Heymann H, Anslyn EV.

Molecules. 2015 May 20;20(5):9170-82. doi: 10.3390/molecules20059170.

13.

Prevalence of Duchenne and Becker muscular dystrophies in the United States.

Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GK, Ciafaloni E, Cunniff C, Druschel CM, Mathews KD, Matthews DJ, Meaney FJ, Andrews JG, Conway KM, Fox DJ, Street N, Adams MM, Bolen J; MD STARnet.

Pediatrics. 2015 Mar;135(3):513-21. doi: 10.1542/peds.2014-2044. Epub 2015 Feb 16. Erratum in: Pediatrics. 2015 May;135(5):945.

14.

Measuring quality of life in muscular dystrophy.

Bann CM, Abresch RT, Biesecker B, Conway KC, Heatwole C, Peay H, Scal P, Strober J, Uzark K, Wolff J, Margolis M, Blackwell A, Street N, Montesanti A, Bolen J.

Neurology. 2015 Mar 10;84(10):1034-42. doi: 10.1212/WNL.0000000000001336. Epub 2015 Feb 6.

15.

The path from childhood behavioural disorders to felony offending: Investigating the role of adolescent drinking, peer marginalisation and school failure.

Savolainen J, Mason WA, Bolen JD, Chmelka MB, Hurtig T, Ebeling H, Nordström T, Taanila A.

Crim Behav Ment Health. 2015 Dec;25(5):375-88. doi: 10.1002/cbm.1931. Epub 2014 Sep 24.

16.

Characteristics and survival of patients with end stage renal disease and spina bifida in the United States renal data system.

Ouyang L, Bolen J, Valdez R, Joseph D, Baum MA, Thibadeau J.

J Urol. 2015 Feb;193(2):558-64. doi: 10.1016/j.juro.2014.08.092. Epub 2014 Aug 25.

17.

Use of state administrative data sources to study adolescents and young adults with rare conditions.

Royer JA, Hardin JW, McDermott S, Ouyang L, Mann JR, Ozturk OD, Bolen J.

J Gen Intern Med. 2014 Aug;29 Suppl 3:S732-8. doi: 10.1007/s11606-014-2925-7.

18.

A comparison of family financial and employment impacts of fragile X syndrome, autism spectrum disorders, and intellectual disability.

Ouyang L, Grosse SD, Riley C, Bolen J, Bishop E, Raspa M, Bailey DB Jr.

Res Dev Disabil. 2014 Jul;35(7):1518-27. doi: 10.1016/j.ridd.2014.04.009. Epub 2014 Apr 20.

19.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M.

Blood. 2014 Jan 30;123(5):632-9. doi: 10.1182/blood-2013-05-504340. Epub 2013 Dec 11.

20.

Takeda's Oncology Discovery Strategy.

DeSchuytner B, Kuvalanka K, Hibner B, Bolen J.

Jpn J Clin Oncol. 2013 Apr;43(4):357-61. doi: 10.1093/jjco/hyt023. Epub 2013 Mar 14. Review.

PMID:
23493743
21.

Health risk behaviors among young adults with spina bifida.

Soe MM, Swanson ME, Bolen JC, Thibadeau JK, Johnson N.

Dev Med Child Neurol. 2012 Nov;54(11):1057-64. doi: 10.1111/j.1469-8749.2012.04402.x. Epub 2012 Sep 3.

22.

Developing an integrated strategy to reduce ethnic and racial disparities in the delivery of clinical preventive services for older Americans.

Shenson D, Adams M, Bolen J, Wooten K, Clough J, Giles WH, Anderson L.

Am J Public Health. 2012 Aug;102(8):e44-50. doi: 10.2105/AJPH.2012.300701. Epub 2012 Jun 14.

23.

Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.

Milhollen MA, Thomas MP, Narayanan U, Traore T, Riceberg J, Amidon BS, Bence NF, Bolen JB, Brownell J, Dick LR, Loke HK, McDonald AA, Ma J, Manfredi MG, Sells TB, Sintchak MD, Yang X, Xu Q, Koenig EM, Gavin JM, Smith PG.

Cancer Cell. 2012 Mar 20;21(3):388-401. doi: 10.1016/j.ccr.2012.02.009.

24.

Potential moderating role of seat belt law on the relationship between seat belt use and adverse health behavior.

Strine TW, Beck L, Bolen J, Okoro C, Li C.

Am J Health Behav. 2012 Jan;36(1):44-55.

PMID:
22251782
25.

Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.

Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB.

Clin Cancer Res. 2011 Dec 15;17(24):7614-24. doi: 10.1158/1078-0432.CCR-11-1536. Epub 2011 Oct 20.

26.

A national profile of health care and family impacts of children with muscular dystrophy and special health care needs in the United States.

Ouyang L, Grosse SD, Fox MH, Bolen J.

J Child Neurol. 2012 May;27(5):569-76. doi: 10.1177/0883073811420719. Epub 2011 Sep 27.

27.

Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.

Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van Ness B, Janz S.

Clin Cancer Res. 2011 Dec 1;17(23):7313-23. doi: 10.1158/1078-0432.CCR-11-0636. Epub 2011 Sep 8.

28.

Health-related quality of life of US adults with arthritis: analysis of data from the behavioral risk factor surveillance system, 2003, 2005, and 2007.

Furner SE, Hootman JM, Helmick CG, Bolen J, Zack MM.

Arthritis Care Res (Hoboken). 2011 Jun;63(6):788-99. doi: 10.1002/acr.20430.

29.

Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea.

Bannerman B, Xu L, Jones M, Tsu C, Yu J, Hales P, Monbaliu J, Fleming P, Dick L, Manfredi M, Claiborne C, Bolen J, Kupperman E, Berger A.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1145-54. doi: 10.1007/s00280-011-1591-2. Epub 2011 Mar 13.

30.

Routine checkups don't ensure that seniors get preventive services.

Shenson D, Adams M, Bolen J, Anderson L.

J Fam Pract. 2011 Jan;60(1):E1-E10.

PMID:
21209970
31.

Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain.

Brushwood DB, Rich BA, Coleman JJ, Bolen J, Wong W.

J Pain Palliat Care Pharmacother. 2010 Dec;24(4):333-48. doi: 10.3109/15360288.2010.524979. Review.

PMID:
21133741
32.

Pillars article: the CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. 1994.

Veillette A, Bookman MA, Horak EM, Bolen JB.

J Immunol. 2010 Sep 1;185(5):2650-7. No abstract available.

33.

Should people who have joint symptoms, but no diagnosis of arthritis from a doctor, be included in surveillance efforts?

Bolen J, Helmick CG, Sacks JJ, Gizlice Z, Potter C.

Arthritis Care Res (Hoboken). 2011 Jan;63(1):150-4. doi: 10.1002/acr.20313. Epub 2010 Jul 27.

34.

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.

Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E, Langston SP, Manfredi M, Narayanan U, Rolfe M, Staudt LM, Soucy TA, Yu J, Zhang J, Bolen JB, Smith PG.

Blood. 2010 Sep 2;116(9):1515-23. doi: 10.1182/blood-2010-03-272567. Epub 2010 Jun 4.

PMID:
20525923
35.

Geographic and sociodemographic variation in self-reported seat belt use in the United States.

Strine TW, Beck LF, Bolen J, Okoro C, Dhingra S, Balluz L.

Accid Anal Prev. 2010 Jul;42(4):1066-71. doi: 10.1016/j.aap.2009.12.014. Epub 2010 Jan 4.

PMID:
20441814
36.

Differences in the prevalence and severity of arthritis among racial/ethnic groups in the United States, National Health Interview Survey, 2002, 2003, and 2006.

Bolen J, Schieb L, Hootman JM, Helmick CG, Theis K, Murphy LB, Langmaid G.

Prev Chronic Dis. 2010 May;7(3):A64. Epub 2010 Apr 15.

37.

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.

Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J.

Cancer Res. 2010 Mar 1;70(5):1970-80. doi: 10.1158/0008-5472.CAN-09-2766. Epub 2010 Feb 16. Erratum in: Cancer Res. 2010 May 1;70(9):3853. Hales, Paul [added].

38.

Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.

Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt AL, Ma J, Loke HK, Lingaraj T, Wu D, Hamman KB, Spelman JJ, Cullis CA, Langston SP, Vyskocil S, Sells TB, Mallender WD, Visiers I, Li P, Claiborne CF, Rolfe M, Bolen JB, Dick LR.

Mol Cell. 2010 Jan 15;37(1):102-11. doi: 10.1016/j.molcel.2009.12.024.

39.
40.

An audience with...Joseph Bolen. Interview by Bethan Hughes.

Bolen J.

Nat Rev Drug Discov. 2009 Aug;8(8):608. doi: 10.1038/nrd2964.

PMID:
19644470
41.

State and metropolitan variation in lack of health insurance among working-age adults, Behavioral Risk Factor Surveillance System, 2006.

Ahluwalia IB, Bolen J, Pearson WS, Link M, Garvin W, Mokdad A.

Public Health Rep. 2009 Jan-Feb;124(1):34-41.

42.

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR, McDonald A, Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei M, Sintchak MD, Talreja T, Thomas MP, Traore T, Vyskocil S, Weatherhead GS, Yu J, Zhang J, Dick LR, Claiborne CF, Rolfe M, Bolen JB, Langston SP.

Nature. 2009 Apr 9;458(7239):732-6. doi: 10.1038/nature07884.

PMID:
19360080
43.

Physicians, patients, and lawsuits-people smarts may play an important role in minimizing the risks of a lawsuit or improving the outcome of pending litigation.

Bolen J.

Pain Med. 2008 Nov;9(8):1146-7. doi: 10.1111/j.1526-4637.2008.00528.x. No abstract available.

PMID:
19067833
44.

Pain and the courtroom--paving the way for a long-overdue showdown.

Bolen J.

Pain Med. 2008 Sep;9(6):750-1. doi: 10.1111/j.1526-4637.2008.00503.x. No abstract available.

PMID:
18816334
45.

Lack of health insurance coverage among working-age adults, evidence from the Behavioral Risk Factor Surveillance System, 1993-2006.

Ahluwalia IB, Bolen J.

J Community Health. 2008 Oct;33(5):293-6. doi: 10.1007/s10900-008-9106-8.

PMID:
18473152
46.

Assessment of the effects of tyrosine protein kinase inhibitors.

Burkhardt AL, Bolen JB.

Curr Protoc Immunol. 2001 May;Chapter 11:Unit 11.5. doi: 10.1002/0471142735.im1105s07.

PMID:
18432706
47.

Immune-complex assays for tyrosine protein kinases.

Burkhardt AL, Bolen JB.

Curr Protoc Immunol. 2001 May;Chapter 11:Unit 11.4. doi: 10.1002/0471142735.im1104s07.

PMID:
18432705
48.

Delivery of preventive services to adults aged 50-64: monitoring performance using a composite measure, 1997-2004.

Shenson D, Adams M, Bolen J.

J Gen Intern Med. 2008 Jun;23(6):733-40. doi: 10.1007/s11606-008-0555-7. Epub 2008 Mar 4.

49.

Acculturation, weight, and weight-related behaviors among Mexican Americans in the United States.

Ahluwalia IB, Ford ES, Link M, Bolen JC.

Ethn Dis. 2007 Autumn;17(4):643-9.

PMID:
18072373
50.

Health insurance coverage and use of selected preventive services by working-age women, BRFSS, 2006.

Ahluwalia IB, Bolen J, Garvin B.

J Womens Health (Larchmt). 2007 Sep;16(7):935-40.

PMID:
17903070

Supplemental Content

Support Center